Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Eszopiclone

FDA-approved product (tablet, oral), marketed as Eszopiclone, Lunesta.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Eszopiclone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Insomnia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzodiazepine related drugs
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Eszopiclone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Eszopiclone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability

    NCT00368056 · start 2005-04

    Registered record
    Registry ID
    NCT00368056
    Conditions
    Primary Insomnia
    Interventions
    Eszopiclone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-04
    Completion
    2006-06
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Insomnia
    InterventionEszopiclone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Testing the Nocturnal Sleep Latency Profile in Primary Insomnia

    NCT00167375 · start 2005-01

    Registered record
    Registry ID
    NCT00167375
    Conditions
    Primary Insomnia; Sleep Initiation and Maintenance Disorders
    Interventions
    eszopiclone 3 mg qHS; General cognitive/behavioral interventions for insomnia
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-01
    Completion
    2007-06
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Insomnia; Sleep Initiation and Maintenance Disorders
    Interventioneszopiclone 3 mg qHS; General cognitive/behavioral interventions for insomnia
    PhaseNot recorded
    Registry statusCompleted

  • 6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia

    NCT00352144 · start 2003-10

    Registered record
    Registry ID
    NCT00352144
    Conditions
    Primary Insomnia
    Interventions
    Eszopiclone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-10
    Completion
    2004-10
    Enrolment
    830

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Insomnia
    InterventionEszopiclone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Eszopiclone With Mild to Moderate Obstructive Sleep Apnea Syndrome (OSAS)

    NCT00685269 · start 2003-08

    Registered record
    Registry ID
    NCT00685269
    Conditions
    Obstructive Sleep Apnea Syndrome
    Interventions
    Eszopiclone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-08
    Completion
    2004-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstructive Sleep Apnea Syndrome
    InterventionEszopiclone; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With Insomnia

    NCT01710631 · start 2001-02

    Registered record
    Registry ID
    NCT01710631
    Conditions
    Primary Insomnia
    Interventions
    eszopiclone 3 mg; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-02
    Completion
    2002-08
    Enrolment
    791

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Insomnia
    Interventioneszopiclone 3 mg; placebo
    PhasePhase 3
    Registry statusCompleted